Search results
Standard therapy for CSU includes second-generation antihistamines and omalizumab. However, many patients tend to be refractory to these therapies. Available treatments such as cyclosporine, dapsone, dupilumab, and tumor necrosis factor alpha (TNFa) inhibitors have been used with success in some cases.
- Expert consensus on practical aspects in the treatment of chronic urticaria
Real-world evidence from the AWARE study in Germany...
- Expert consensus on practical aspects in the treatment of chronic urticaria
The recommended dose for the treatment of chronic spontaneous urticaria is 300 mg by subcutaneous injection every 4 weeks. Some patients may achieve control of their symptoms with a dose of 150 mg every 4 weeks.
8 sie 2022 · The recommendations for the use of first-line treatment (antihistamine), second-line treatment (omalizumab), and third-line treatment (cyclosporine) now include guidance on updosing and duration (Fig 3, A and B).
26 wrz 2024 · Second-generation H 1 antihistamines are first-line treatment, omalizumab is second-line treatment, and cyclosporine is third-line treatment for chronic spontaneous urticaria.
Real-world evidence from the AWARE study in Germany highlights the need for greater awareness of guideline recommendations for the treatment of patients with H1-antihistamine-refractory chronic spontaneous urticaria. 2019.
27 lip 2024 · Treatment of chronic spontaneous urticaria with benralizumab: report of primary endpoint per-protocol analysis and exploratory endpoints
17 lis 2023 · Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria, is defined by the presence of urticaria (hives) on most days of the week for a duration of six weeks or longer [1]. Associated angioedema occurs in approximately 40 percent of patients.
